NGS test completed in one day, lung and colon cancer test kits receive FDA approval
NGS (next generation sequencing technology), also known as high-throughput sequencing technology. It is commonly used for genetic disease screening, prenatal testing or diagnosis, oncology clinical diagnosis, pharmacogenomic testing, cancer chemotherapy and treatment, and single gene disease screening or diagnosis. It is capable of sequencing hundreds of thousands to millions of DNA molecules in parallel at one time, with fast analysis speed, high accuracy, and short time.
NGS testing is currently used in clinical settings to evaluate the availability of appropriate immunotherapeutic agents or targeted drugs, and to test patients with a family history of genetic tumors and both parents or close relatives to determine the type of genetic disease, to test relatives for disease, to assess the risk of disease, and to assess the risk to the reproductive system.
Pillar Biosciences is a global oncology precision diagnostic solutions company, but its NGS tests are unrelated to the NGS testing platform. The company has developed SLIMamp® and PiVAT® using AI technology to reduce traditional NGS testing time from days to one day, and requires less DNA quantity to provide valid test results even if the test sample is damaged.
Source: https://www.vbdata.cn/1518859894
Related Posts
Leto Laboratories Completes Series C Financing of Over 100 Million RMB, Focusing on 0 to 1 Innovative Protein Design and Manufacturing Platform Construction
Leto Laboratories announced the completion of its Series C financing round with a funding size of over 100 million RMB. This round of financing was led by Zhongguancun Science City Corporation and followed by Infiniti Capital and HB Ventures. The round was mainly used for the clinical research of LTC004, a new-generation anti-tumor cytokine class […]
Leto Laboratories Developing Semaglutide Biosimilar for Diabetes, Currently in Phase II Clinical Trial (2025)
Leto Laboratories is developing a Semaglutide biosimilar for diabetes and weight loss treatment, currently in Phase II clinical trials. The therapeutic candidate targets the GLP-1 receptor. According to GlobalData, Phase II diabetes drugs have a 38% success rate to advance to Phase III. Leto leverages its high-throughput screening and directional protein refold
Pillar Biosciences Raises $34.5 Million to Accelerate Precision Medicine Innovation
In May 2025, Pillar Biosciences announced it had raised $34.5 million in funding, with participation from Illumina, Soleus Capital, and existing investors. The proceeds will be used to expand commercial activities, strengthen partnerships with biopharma companies, and accelerate the adoption of its distributable clinical testing kits worldwide. Pillar’s SLIMa
FDA Approves IND for LAE120, a Novel USP1 Inhibitor for Advanced Solid Tumors (March 4, 2025)
In March 2025, Laekna announced that the FDA approved the IND for LAE120, a novel USP1 inhibitor developed internally for advanced solid tumors. LAE120 shows potent monotherapy anti-tumor activity and synergy with PARP inhibitors, especially in homologous recombination deficiency (HRD) cancers. It demonstrated strong tumor inhibition in various xenograft models
Leave a Reply